Nab paclitaxel
Nab paclitaxel is a pharmaceutical drug with 128 clinical trials. Currently 63 active trials ongoing. Historical success rate of 65.2%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
36
Early Stage
75
Mid Stage
15
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
50.0%
15 of 30 finished
50.0%
15 ended early
63
trials recruiting
128
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Clinical Trials (128)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Study of DF1001 in Patients With Advanced Solid Tumors
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 128